Influence of treatment center and hospital volume on survival for locally advanced cervical cancer
- PMID: 26177552
- PMCID: PMC4679418
- DOI: 10.1016/j.ygyno.2015.07.015
Influence of treatment center and hospital volume on survival for locally advanced cervical cancer
Abstract
Objective: Procedural volume is associated with outcomes for many surgical interventions. Little is known about the association between volume and outcomes of radiation. We examined the association between treatment center and hospital volume and outcomes for women with locally advanced cervical cancer treated with radiation.
Methods: Women with stage IIB-IVA cervical cancer treated with primary radiation from 1998 to 2011 and recorded in the National Cancer Database were examined. Hospital volume was estimated as the mean annualized volume, while center-specific effects on care were examined using a hospital-specific random effect. Multivariable regression models adjusted for metrics of treatment quality were used to estimate survival.
Results: 20,766 patients treated at 1115 hospitals were identified. The median follow-up was 24.2months while 5-year survival was 36.5% (95% CI, 35.6-37.4%). Higher hospital volume was associated with receipt of brachytherapy (P<0.05), but had no effect on use of chemotherapy. In a multivariable model accounting for clinical and demographic factors as well as quality of care, hospital volume was not associated with survival (P=0.25). The specific hospital in which patients received care was the strongest predictor of survival (P<0.0001) followed by stage, year of diagnosis and treatment quality (P<0.0001 for all). The hospital-specific effect on mortality expressed as a hazard ratio, ranged from 0.66 to 1.53 across hospitals.
Conclusion: For locally advanced cervical cancer, hospital volume has a minimal impact on outcome; however, the specific center in which care is delivered is strongly associated with survival.
Keywords: Cervical cancer; Chemoradiation; Chemosensitization; Outcomes; Radiation; Volume.
Copyright © 2015 Elsevier Inc. All rights reserved.
Figures

Similar articles
-
Impact of facility volume on therapy and survival for locally advanced cervical cancer.Gynecol Oncol. 2014 Feb;132(2):416-22. doi: 10.1016/j.ygyno.2013.12.013. Epub 2013 Dec 12. Gynecol Oncol. 2014. PMID: 24333361
-
Clinical outcomes of definitive chemoradiation followed by intracavitary pulsed-dose rate image-guided adaptive brachytherapy in locally advanced cervical cancer.Gynecol Oncol. 2015 Nov;139(2):288-94. doi: 10.1016/j.ygyno.2015.09.008. Epub 2015 Sep 11. Gynecol Oncol. 2015. PMID: 26364808
-
Distance from a Comprehensive Cancer Center: A proxy for poor cervical cancer outcomes?Gynecol Oncol. 2016 Dec;143(3):617-621. doi: 10.1016/j.ygyno.2016.10.004. Epub 2016 Oct 6. Gynecol Oncol. 2016. PMID: 27720232 Free PMC article.
-
Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early-stage, cervical carcinoma.Cancer. 2003 May 1;97(9):2196-202. doi: 10.1002/cncr.11371. Cancer. 2003. PMID: 12712471 Review.
-
Stage at diagnosis and mortality in patients with adenocarcinoma and adenosquamous carcinoma of the uterine cervix diagnosed as a consequence of cytologic screening.Acta Cytol. 2003 Mar-Apr;47(2):167-71. doi: 10.1159/000326498. Acta Cytol. 2003. PMID: 12685183 Review.
Cited by
-
Racial disparities in receipt of radiation and brachytherapy in cervical cancer patients: Do they exist in a SEER-Medicare population?Gynecol Oncol Rep. 2024 Sep 19;55:101505. doi: 10.1016/j.gore.2024.101505. eCollection 2024 Oct. Gynecol Oncol Rep. 2024. PMID: 39376712 Free PMC article.
-
Emerging Roles of m6A RNA Methylation Regulators in Gynecological Cancer.Front Oncol. 2022 Jan 28;12:827956. doi: 10.3389/fonc.2022.827956. eCollection 2022. Front Oncol. 2022. PMID: 35155260 Free PMC article.
-
The value of volume.J Gynecol Oncol. 2022 Jan;33(1):e17. doi: 10.3802/jgo.2022.33.e17. Epub 2021 Nov 22. J Gynecol Oncol. 2022. PMID: 34910398 Free PMC article. No abstract available.
-
Association of Hospital Surgical Volume With Survival in Early-Stage Cervical Cancer Treated With Radical Hysterectomy.Obstet Gynecol. 2023 Jan 1;141(1):207-214. doi: 10.1097/AOG.0000000000005026. Epub 2022 Nov 30. Obstet Gynecol. 2023. PMID: 36701621 Free PMC article.
-
Systematic Review and Meta-analysis of the Association Between Radiation Therapy Treatment Volume and Patient Outcomes.Int J Radiat Oncol Biol Phys. 2023 Dec 1;117(5):1063-1086. doi: 10.1016/j.ijrobp.2023.02.048. Epub 2023 May 25. Int J Radiat Oncol Biol Phys. 2023. PMID: 37227363 Free PMC article.
References
-
- Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137–43. - PubMed
-
- Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144–53. - PubMed
-
- Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154–61. - PubMed
-
- Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17:1339–48. - PubMed
-
- NCI Issues Clinical Announcement on Cervical Cancer [Accessed October, 12, 2014];Chemotherapy Plus Radiation Improves Survival. at http://www.nih.gov/news/pr/feb99/nci-22.htm.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical